First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics (TRAX) shares rose 3.8% after Guggenheim initiated coverage with a Buy rating and $100 price target, citing confidence in its anti-CD122 target and lead asset ANB033 for autoimmune diseases. Guggenheim analyst Yatin Suneja highlighted the company's unique position as the only publicly traded small-to-mid cap firm developing an anti-CD122 monoclonal antibody.
Ware J. Anthony sold 39,265 shares of First Tracks Biotherapeutics, Inc. (TRAX) at $44.78 ($1.76M total) on 2026-09-02.
First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TRAX (First Tracks Biotherapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent TRAX coverage spans market movers, insider activity and earnings.
In the last 30 days, TRAX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.8M). The most active reporter was Ware J. Anthony with 1 filing.
Analyst upgrade likely supports short-term upside.
Insider sale may signal lack of confidence, potentially pressuring the stock short-term.
Fast Track designation plus reaffirmed Phase 1b timelines improve regulatory and clinical optionality for ANB033, while cash runway guidance reduces near-term financing risk.
New Phase 1 starts and FDA end-of-Phase 2 progress can improve perceived clinical probability and risk-adjusted pipeline value.
This is more of a momentum and pipeline update than a discrete new catalyst, but it can support sentiment.
AlphAI scores every news story that mentions TRAX with an AI model for sentiment and relevance, and aggregates insider trades from First Tracks Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
First Tracks Biotherapeutics (TRAX) shares rose 3.8% after Guggenheim initiated coverage with a Buy rating and $100 price target, citing confidence in its anti-CD122 target and lead asset ANB033 for autoimmune diseases. Guggenheim analyst Yatin Suneja highlighted the company's unique position as the only publicly traded small-to-mid cap firm developing an anti-CD122 monoclonal antibody.
1 min readWare J. Anthony sold 39,265 shares of First Tracks Biotherapeutics, Inc. (TRAX) at $44.78 ($1.76M total) on 2026-09-02.
1 min readFirst Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2
5 min readThe following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.
6 min readBiotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
6 min readBiotech stocks hit 52-week highs on July 9, 2026. First Track Biotherapeutics (TRAX) rose 55.99% to $32.40 on Phase 1 trial starts and an FDA end-of-Phase 2 meeting. BridgeBio Pharma (BBIO) closed at $93.52, up 15.12%, citing Acoramidis and Phase 3 plans. Monopar (MNPR), 10x Genomics (TXG) and MapLight (MPLT) also reached highs amid clinical updates.
6 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readFirst Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0002091349 false 0002091349 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,
2 min readTraxtion said it has completed an $86m equity capital raise to fund its long-term plan to revitalise South Africa’s rail sector. The round includes STANLIB Infrastructure Investments, Standard Bank and Harith InfraCo, via minority stakes. Traxtion said the equity closes funding for its R3.4bn rolling stock programme (46 locomotives, 920 wagons) and supports further refurbishment and expansion.
4 min readTurn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.
7 min read
